Disease Diagnosis TRIZ Cases

Combining short peptides and dimers increases diagnostic sensitivity to 80% for early schizophrenia detection in children.

Measuring TRAIL protein levels in blood samples to determine viral infection patient risk categories.

CENP-A labelling detects oncogenic transformations via nuclear patterns to predict treatment response and resolve diagnostic accuracy trade-offs.

Skin biopsy biomarkers quantify therapeutic response to replace subjective clinical assessments.

Antibodies target free histone epitopes to resolve detection reliability and procedure complexity trade-offs.

Measuring urinary IGFBP7 and TIMP-2 concentrations enables early identification of acute kidney injury risk in patients undergoing therapeutic interventions.

A biomarker panel detects liver disease stages using blood-based protein measurements.

Angiopoietin-2 concentration in body fluids predicts colorectal cancer clinical outcomes and treatment responses.

Immunofluorescence staining of HD5 proteins classifies Paneth cell phenotypes, resolving background staining issues in Crohn's disease prognosis.

Targeting the 5'UTR of alpha-synuclein mRNA limits protein synthesis, addressing insufficient specificity in existing therapies.

Multi-receptor assay evaluates 5-HT1a, 5-HT1d, and 5-HT7 binding to select candidates with reduced anxiety side effects.

Measuring selenoprotein P protein concentration enables non-invasive pulmonary hypertension screening via simple blood sampling.

Determines concentrations of multiple constituents using ICP-MS to differentiate prostate cancer from benign conditions.

PSP/reg biomarker thresholds guide antibiotic initiation, reducing resistance caused by delayed culture results.

Antibody-based detection overcomes low sensitivity and cell loss from density gradient centrifugation.

A method measures IL-8, IL-10, TNF-Alpha, and total IgE proteins in biological samples to identify non-coeliac gluten sensitivity biomarkers.

Targeted exon 8 disruption creates a reliable animal model for screening therapeutic compounds against developmental and muscular disorders.

MHC multimer assay detects amyloid precursor protein-specific CD8+ T cells to diagnose late-onset Alzheimer's disease despite unreliable mouse models.

Calculating a serum Tau-A to Tau-C ratio index predicts Alzheimer's progression, replacing invasive cerebrospinal fluid sampling with accessible blood testing.

ABCA1 and TMEM245 gene expression levels identify patients responding to immune checkpoint inhibitors, resolving unpredictable treatment effectiveness.

Functionalized adhesion areas in a microfluidic channel quantify red blood cell detachment forces, enabling patient-specific sickle cell disease prognosis.

Recombinant platelet glycoprotein Ibα with gain-of-function mutations measures von Willebrand factor function, eliminating ristocetin-induced imprecision.

Detecting circulating extracellular vesicle PD-L1 levels enables precise identification of patients likely to respond to immune checkpoint blockade therapies.

Segmented autoantigen arrays measure distinct antibody levels to differentiate Alzheimer's disease from other neurological conditions.

Sandwich assays quantify MR-proADM biomarkers to resolve diagnostic reliability contradictions in neurodegenerative disease detection.

Flow cytometry measures neutrophil fluorescence and microparticle concentration for rapid DIC detection.

A diagnostic method uses platelet surface protein expression levels to predict patient benefit from immune checkpoint inhibitor therapy.

Logistic functions of mean cell hemoglobin and volume calculate iron deficiency indices, resolving low specificity in chronic inflammation.

Segmented antibody detection and parameter thresholds differentiate tumor from immune cell staining to improve therapeutic response prediction.

Fatty acid ratios in blood samples assess de novo lipogenesis activity, resolving the trade-off between measurement accuracy and clinical applicability.

Immunopurification using agarose beads enriches anti-PF4 antibodies to improve detection accuracy while managing device complexity.

Quantifying CD14+/CD16- monocytes via flow cytometry resolves diagnostic ambiguity, reducing time and misidentification risks inherent in complex WHO criteria.

A biomarker panel detects WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 in body fluids to support clinical assessment.

Stratifying MS patients by CD27- Th1 CD4+ cell levels enables targeted antigen-specific tolerization, reducing side effects from nonspecific immunosuppression.

Segmented blood profiling detects HbA1c alterations to resolve diabetes diagnostic precision trade-offs.

A liquid kidney biopsy reagent kit utilizes monoclonal antibodies to detect galactose-deficient IgA1 and IgG autoantibodies in blood samples.

NK cell cytotoxicity measurement determines patient susceptibility to SARS-CoV-2 infection, resolving diagnostic sensitivity and specificity limitations.

Quantifying specific cytokines replaces subjective clinical assessment, enabling precise early detection of chronic graft-versus-host disease.

Measuring specific lysophosphatidic acid levels enables personalized treatment selection for inflammatory respiratory diseases.

Immobilized leukocyte extravasation factors capture diseased cells on microfluidic surfaces for rapid optical detection.

Peptide biomarkers replace invasive angiography with blood tests, resolving the trade-off between diagnostic accuracy and patient safety.

Multiplexed phospho-flow cytometry detects neoplastic cell subsets using surface and intracellular markers.

A diagnostic method calculates the ratio of cysteinyl leukotriene production to eosinophilic airway inflammation levels for targeted treatment.

Machine learning analyzes oxidized amino acid residues in plasma to differentiate autistic spectrum disorder cases.

Segmenting a core antigen set into p53, SSX1, and p62 or KOC resolves sensitivity trade-offs across ethnic populations.

FRAC replaces labor-intensive microscopy with ratiometric fluorescence to quantify centriole quality and diagnose male infertility.